title: Treatment with ezetimibe in kidney transplant recipients with uncontrolled dyslipidemia.
abstract: BACKGROUND
  Cardiovascular disease is the leading cause of death in kidney transplant recipients. Hyperlipidemia is a cardiovascular risk factor present in over 70% of recipients. Ezetimibe has proved effective for the treatment of dyslipidemia in these patients.
  
  
  OBJECTIVE
  To evaluate the efficacy and safety of treatment with ezetimibe in kidney transplant recipients with uncontrolled hyperlipidemia.
  
  
  METHODS
  We undertook a prospective study of 25 kidney transplant recipients with dyslipidemia who started treatment with 10 mg of ezetimibe. Statins were being taken by 96% of these patients. Monotherapy was used in one case. Measurements were made at baseline and after 3, 6, and 12 months of the lipid and hepatic profiles, CPK, lactose dehydrogenase, renal function and levels of immunosuppressive agents.
  
  
  RESULTS
  A significant reduction was noted in total cholesterol, low-density lipoprotein cholesterol, and triglycerides. No patient had changes in the hepatic profile, increased CPK and lactose dehydrogenase levels, or important adverse effects. Renal function remained stable, with no significant variations in plasma levels of the different immunosuppressive agents.
  
  
  CONCLUSIONS
  The use of ezetimibe associated with statins is an efficient and safe therapeutic alternative for the treatment of poorly controlled dyslipidemia in recipients of a kidney graft.
authors.affiliation: Nephrology Department, Hospital Universitario Carlos Haya, Malaga, Spain. verolopezjim@yahoo.es
authors.forename: V
authors.initials: V
authors.lastname: López
authors.forename: C
authors.initials: C
authors.lastname: Gutiérrez
authors.forename: E
authors.initials: E
authors.lastname: Gutiérrez
authors.forename: E
authors.initials: E
authors.lastname: Sola
authors.forename: M
authors.initials: M
authors.lastname: Cabello
authors.forename: D
authors.initials: D
authors.lastname: Burgos
authors.forename: M
authors.initials: M
authors.lastname: González Molina
mesh_terms: D000328:Adult; D000368:Aged; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D001384:Azetidines / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000453:epidemiology; D002784:Cholesterol / Q000097:blood; D003402:Creatine Kinase / Q000097:blood; D004359:Drug Therapy, Combination; D050171:Dyslipidemias / Q000188:drug therapy*; D000069438:Ezetimibe; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000009:adverse effects / Q000276:immunology; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D014280:Triglycerides / Q000097:blood
chemical_list: D000924:Anticholesteremic Agents; D001384:Azetidines; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007166:Immunosuppressive Agents; D008055:Lipids; D014280:Triglycerides; D002784:Cholesterol; D007770:L-Lactate Dehydrogenase; D003402:Creatine Kinase; D000069438:Ezetimibe